

PRODUCT INFORMATION



Teduglutide

Item No. 43906

CAS Registry No.: 197922-42-2

Formal Name: L-histidylglycyl-L- α -aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L- α -aspartyl-L- α -glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L- α -aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L- α -aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutamyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-aspartic acid

H—His—Gly—Asp—Gly—Ser—Phe—Ser—Asp—Glu—Met—
Asn—Thr—Ile—Leu—Asp—Asn—Leu—Ala—Ala—Arg—
Asp—Phe—Ile—Asn—Trp—Leu—Ile—Gln—Thr—Lys—
Ile—Thr—Asp—OH

Synonyms: ALX-0600, [Gly²]hGLP-2

MF: C₁₆₄H₂₅₂N₄₄O₅₅S

FW: 3,752.1

Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Teduglutide is supplied as a solid. A stock solution may be made by dissolving the teduglutide in the solvent of choice, which should be purged with an inert gas. Teduglutide is slightly soluble (0.1-1 mg/ml) in acetonitrile:water (1:1).

Description

Teduglutide is a peptide agonist of the glucagon-like peptide 2 receptor (GLP-2R) and a derivative of human GLP-2 that contains a glycine instead of alanine in position 2.¹ It selectively induces GLP-2R- over GLP-1R-mediated transcriptional activity in reporter assays using HEK293 cells (EC₅₀s = 0.09 and >1,000 nM, respectively). Teduglutide (0.1 mg/kg twice per day) increases small and large bowel mass and jejunal and ileal villus height in mice.² It also activates prodynorphin-expressing neurons in the ventromedial hypothalamus (VMH^{Pdyn}) and inhibits weight gain, body fat increase, hyperphagia, and glucose intolerance induced by olanzapine (Item No. 11937) in mice when administered at a dose of 10 μ g per animal for three months.³ Formulations containing teduglutide have been used in the treatment of short bowel disorder.

References

1. Wiśniewski, K., Sueiras-Diaz, J., Jiang, G., *et al.* Synthesis and pharmacological characterization of novel glucagon-like peptide-2 (GLP-2) analogues with low systemic clearance. *J. Med. Chem.* **59(7)**, 3129-3139 (2016).
2. Drucker, D.J., DeForest, L., and Brubaker, P.L. Intestinal response to growth factors administered alone or in combination with human [Gly²]glucagon-like peptide 2. *Am. J. Physiol.* **273(6)**, G1252-G1262 (1997).
3. Peng, Y., Feng, C., Peng, S., *et al.* GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice. *Nat. Metab.* **7(4)**, 730-741 (2025).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/04/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM